Olga Sala-Torra
Overview
Explore the profile of Olga Sala-Torra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vedula R, Karp H, Koob J, Lim F, Garcia J, Winer E, et al.
Blood
. 2024 Jul;
144(12):1290-1299.
PMID: 38976877
Fusion oncogenes can be cancer-defining molecular alterations that are essential for diagnosis and therapy selection.1,2 Rapid and accessible molecular diagnostics for fusion-driven leukemias such as acute promyelocytic leukemia (APL), Philadelphia...
2.
Sala-Torra O, Beppu L, Wu Q, Welch E, Berthier E, Radich J, et al.
Leukemia
. 2024 Jun;
38(8):1822-1824.
PMID: 38879611
No abstract available.
3.
Yeung C, Eacker S, Sala-Torra O, Beppu L, Woolston D, Liachko I, et al.
medRxiv
. 2024 Jun;
PMID: 38853970
Background: Cytogenetic analysis encompasses a suite of standard-of-care diagnostic testing methods that is routinely applied in cases of acute myeloid leukemia (AML) to assess chromosomal changes that are clinically relevant...
4.
Sala-Torra O, Reddy S, Hung L, Beppu L, Wu D, Radich J, et al.
PLOS Glob Public Health
. 2023 Sep;
3(9):e0002267.
PMID: 37699001
Recurrent gene fusions are common drivers of disease pathophysiology in leukemias. Identifying these structural variants helps stratify disease by risk and assists with therapy choice. Precise molecular diagnosis in low-and-middle-income...
5.
Cassaday R, Zarling L, Garcia K, Sala-Torra O, Stevenson P, Martino C, et al.
Leuk Lymphoma
. 2023 Mar;
64(5):927-937.
PMID: 36938892
Treatments for adults with newly-diagnosed acute lymphoblastic leukemia (ALL) may be prohibitively toxic and/or resource-intense. To address this, we performed a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide,...
6.
Sala-Torra O, Beppu L, Abukar F, Radich J, Yeung C
Blood Adv
. 2022 Apr;
6(12):3590-3592.
PMID: 35420676
No abstract available.
7.
Reddy S, Hung L, Sala-Torra O, Radich J, Yeung C, Yeung K
BMC Genomics
. 2021 Aug;
22(1):626.
PMID: 34425749
Background: Long-read sequencing has great promise in enabling portable, rapid molecular-assisted cancer diagnoses. A key challenge in democratizing long-read sequencing technology in the biomedical and clinical community is the lack...
8.
Yeung C, Qu X, Sala-Torra O, Woolston D, Radich J, Fang M
Cancer Med
. 2021 Jul;
10(16):5629-5642.
PMID: 34288525
Background: Comprehensive molecular and cytogenetic profiling of acute lymphoblastic leukemia (ALL) is important and critical to the current standard of care for patients with B-acute lymphoblastic leukemia (B-ALL). Here we...
9.
Foss E, Radulovic D, Stirewalt D, Radich J, Sala-Torra O, Pogosova-Agadjanyan E, et al.
J Proteome Res
. 2012 Aug;
11(10):5005-10.
PMID: 22900933
Despite immense interest in the proteome as a source of biomarkers in cancer, mass spectrometry has yet to yield a clinically useful protein biomarker for tumor classification. To explore the...
10.
Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M, et al.
Cancer Cell
. 2011 Nov;
20(5):661-73.
PMID: 22094259
Using a mouse model recapitulating the main features of human chronic myelogenous leukemia (CML), we uncover the hierarchy of leukemic stem and progenitor cells contributing to disease pathogenesis. We refine...